Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome

Proc Natl Acad Sci U S A. 1987 Nov;84(22):8044-8. doi: 10.1073/pnas.84.22.8044.


Down syndrome, the phenotypic expression of human trisomy 21, is presumed to result from a 1.5-fold increase in the expression of the genes on human chromosome 21. As an approach to the development of an animal model for Down syndrome, several strains of transgenic mice that carry the human Cu/Zn-superoxide dismutase gene have been prepared. These animals express the transgene in a manner similar to that of humans, with 0.9- and 0.7-kilobase transcripts in a 1:4 ratio, and synthesize the human enzyme in an active form capable of forming human-mouse enzyme heterodimers. Cu/Zn-superoxide superoxide dismutase activity is increased from 1.6- to 6.0-fold in the brains of four transgenic strains and to an equal or lesser extent in several other tissues. These animals provide a unique system for studying the consequences of increased dosage of the Cu/Zn-superoxide dismutase gene in Down syndrome and the role of this enzyme in a variety of other pathological processes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alzheimer Disease / enzymology
  • Alzheimer Disease / genetics
  • Animals
  • Brain Chemistry
  • Disease Models, Animal*
  • Down Syndrome / enzymology*
  • Down Syndrome / genetics
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Mice
  • Mice, Transgenic*
  • Recombinant Proteins / analysis
  • Recombinant Proteins / genetics*
  • Superoxide Dismutase / analysis
  • Superoxide Dismutase / genetics*


  • Recombinant Proteins
  • Superoxide Dismutase